Publicacións en colaboración con investigadores/as de Universitat de València (37)

2024

  1. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine

    Pharmacological Research, Vol. 200

  2. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  3. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7

  2. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

2020

  1. Interaction between the functional SNP rs2070951 in NR3C2 gene and high levels of plasma corticotropin-releasing hormone associates to postpartum depression

    Archives of Women's Mental Health, Vol. 23, Núm. 3, pp. 413-420

  2. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

  3. The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme

    Social Psychiatry and Psychiatric Epidemiology, Vol. 55, Núm. 5, pp. 645-657

2019

  1. Assessing cross-national invariance of the Community Assessment of Psychic Experiences (CAPE)

    Psychological Medicine, Vol. 49, Núm. 15, pp. 2600-2607

  2. Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration

    Pharmaceutics, Vol. 11, Núm. 8

  3. Relation Between Genetic Factors and Frailty in Older Adults

    Journal of the American Medical Directors Association, Vol. 20, Núm. 11, pp. 1451-1457

2018

  1. Human Early Life Exposome (HELIX) study: A European population-based exposome cohort

    BMJ Open, Vol. 8, Núm. 9

  2. Identification of single nucleotide polymorphisms related to frailty

    Revista Espanola de Geriatria y Gerontologia, Vol. 53, Núm. 4, pp. 202-207

  3. Treated incidence of psychotic disorders in the multinational EU-GEI study

    JAMA Psychiatry, Vol. 75, Núm. 1, pp. 36-46

2017

  1. Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Identificación de polimorfismos de nucleótido simple en centenarios

    Revista Espanola de Geriatria y Gerontologia, Vol. 51, Núm. 3, pp. 146-149

2015

  1. No major host genetic risk factor contributed to A(H1N1)2009 influenza severity

    PLoS ONE, Vol. 10, Núm. 9